Thus, Shih et al. have reported the development of a combination therapy based on the study of a mouse model generated using combined transformation with mutant TET2, FLT3-ITD, and IDH2-R140Q; thus, triple-transformed leukemia resulted to be sensitive to 5-azacytidine or to the IDH2 inhibitor enasidenib [145]. Here, IDH2 is linked to leukemia.